.... A total of 65,775 sICH-free controls were randomly selected at a ratio of 1:15 from individuals with the same birth year and sex according to a nested case-control study design. Results: Although the incidence rate of sICHs started to decrease from 2007 onward, the use of antiplatelets, anticoagulants...

... anticoagulation in patients with atrial fibrillation (AF). Although rivaroxaban is widely prescribed to reduce their risk of stroke in patients with nonvalvular AF (NVAF), the real-world evidence on rivaroxaban treatment is limited. We aimed to examine the outcomes of rivaroxaban treatment in NVAF patients...

...John W.P. Wong; Leonid Churilov; Richard Dowling; Peter Mitchell; Steven Bush; Lasheta Kanesan; Bernard Yan Background/Aim: Endovascular thrombectomy may be performed in anticoagulated patients taking vitamin-K antagonists (VKA) or direct-acting oral anticoagulants (DOAC) in whom the use...

...Leila H. Borowsky; Susan Regan; Yuchiao Chang; Alison Ayres; Steven M. Greenberg; Daniel E. Singer Background: Atrial fibrillation (AF) is a major cause of ischemic stroke. Individuals with undiagnosed AF lack the stroke protection afforded by oral anticoagulants. We obtained a contemporary...

...; Christian Foerch Background: The first specific antidote for non-vitamin K antagonist oral anticoagulants (NOAC) has recently been approved. NOAC antidotes will allow specific treatment for 2 hitherto problematic patient groups: patients with oral anticoagulant therapy (OAT)-associated intracerebral...

...Asako Nakamura; Junya Kuroda; Tetsuro Ago; Jun Hata; Ryu Matsuo; Shuji Arakawa; Takahiro Kuwashiro; Masahiro Yasaka; Yasushi Okada; Takanari Kitazono; Masahiro Kamouchi; on behalf of the Fukuoka Stroke Registry Investigators Background: Oral anticoagulants (OACs) reduce the incidence of embolic...

...Celine S. Gathier; Ale Algra; Gabriël J.E. Rinkel; H. Bart van der Worp Background: For patients who survive intracerebral haemorrhage (ICH) during treatment with oral anticoagulation (OAC), the balance between the benefits and risks of restarting OAC is unclear. The decision to restart OAC...

...Ale Algra This paper summarises the benefits and risks of anticoagulant treatment in patients who have had cerebral ischaemia. In patients with a cardiac source of embolism (in most studies atrial fibrillation), anticoagulation with a target intensity of an INR of 2.0–3.0 is the therapy of first...

...Joan Martí-Fàbregas; José Mateo Vitamin K antagonists are the only oral anticoagulants available and are considered as well-established treatment to prevent a first stroke or a recurrent stroke in patients with atrial fibrillation. The difficulties in the routine management of these patients cause...

...P.H.A. Halkes; A. Algra In this paper, an overview is given of trials with oral anticoagulants and dipyridamole in the secondary prevention after transient ischaemic attack or minor stroke. In patients with atrial fibrillation, the secondary preventive treatment of first choice is oral...

... determined whether the use of oral antithrombotic therapy and the patients’ preexisting comorbidities were predictive of cerebellar hemorrhage (CH; previously reported to be associated with anticoagulants) as compared to other ICH, and whether antithrombotic therapy affected the clinical severity of CH...

... endpoints and hemorrhages Cryptogenic stroke Anticoagulants Antiplatelet therapy Recurrent stroke Antithrombotic therapy, including oral anticoagulants and antiplatelet agents, are part of the major medical treatments available for the primary and secondary prevention of stroke...

... pretreatment does not increase the risk of symptomatic bleeding after systemic thrombolysis with rt-PA, even if thrombolysis is followed by anticoagulation. 21 05 2002 16 12 2002 18 7 2003 Between March 1996 and August 2001, 300 consecutive patients with acute ischemic stroke were...

...-dose aspirin with anticoagulants may provide better protection against thromboembolic events compared to anticoagulants alone in high-risk patients with atrial fibrillation. Objective: Evaluation of the preventive efficacy against nonfatal thromboembolic events and vascular deaths of the combination...

...., Massachusetts General Hospital, Boston, Mass., Buffalo General Hospital, Buffalo, N.Y., USA The Feasibility of a Collaborative Double-Blind Study Using an Anticoagulant The Warfarin-Aspirin Recurrent Stroke Study (W ARSS) The Antiphospholipid Antibodies and Stroke Study (APASS) The Patent Foramen Ovale...

... of the antithrombotic and surgical strategies will be presented. 30 3 1994 Ccrebrovasc Dis 1994;4(suppl 1): 16-25 lï.J.M. Barnett The John P. Robarts Research Institute, London, Ontario, Canada Drug and Surgical Issues in Stroke Prevention Key Words Anticoagulants Antiaggregants Carotid endarterectomy...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. TIA Clustering TIA Stroke prognosis Lacunar stroke Anticoagulants Small vessel disease Original Paper Cerebrovasc Dis 1993:3:213-220 Manuela Crespo Teresa P. Meló...